JP Morgan Chase
KROS icon

JP Morgan Chase’s Keros Therapeutics KROS Stock Holding History

JP Morgan Chase’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,200
Closed -$212K – 7581
2024
Q1 		$212K Buy
+3,200
New +$190K ﹤0.01% 5320

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

JP Morgan Chase's KROS Position: Q1 2026 in Review

JP Morgan Chase increased its Keros Therapeutics (KROS) stake by 102% in Q1 2026, buying an estimated $294K and bringing the position to 37,680 shares worth $402K. The position accounts for ﹤0.01% of the portfolio, ranked #5152.

JP Morgan Chase first reported a position in KROS in Q2 2020 and has held it in 24 quarters since. The position peaked at $26.5M in Q1 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • JP Morgan Chase held 37,680 shares of Keros Therapeutics worth $402K as of Q1 2026.
  • JP Morgan Chase bought 19,042 Keros Therapeutics shares in Q1 2026, an estimated $294K.
  • Keros Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5152 holding.
  • JP Morgan Chase first reported a position in Keros Therapeutics in Q2 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Keros Therapeutics position peaked at $26.5M in Q1 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.